Share：
Share this content in WeChat
X
[Chinese] [PDF] 28 1
• Clinical Article •
Predictive value of MRI parameter values for prognosis of patients with hepatocellular carcinoma
CHEN Binbin  ZHAO Wensi 

Cite this article as CHEN B B, ZHAO W S. Predictive value of MRI parameter values for prognosis of patients with hepatocellular carcinoma[J]. Chin J Magn Reson Imaging, 2026, 17(6): 79-85. DOI:10.12015/issn.1674-8034.2026.06.010.


[Abstract] Objective To explore the predictive value of parameters of magnetic resonance imaging (MRI) for the prognosis of patients with hepatocellular carcinoma.Materials and Methods The clinical data of 123 patients with hepatocellular carcinoma admitted to the First People's Hospital of Changde City from January 2021 to January 2024 were retrospectively selected as the hepatocellular carcinoma group. After one year of follow-up after hepatocellular carcinoma resection, MRI examination found metastases in the liver or other organs, which were judged as tumor metastasis or recurrence. Among them, 37 cases of metastasis or recurrence were selected as the early recurrence group, 86 cases were selected as the no early recurrence group, and clinical data of 123 patients with benign liver lesions were collected as the benign liver lesion group. The clinical data, MRI parameter values and MRI parameter values of different pathological features were compared among the groups. The early recurrence group was included in the positive group, and the non-early recurrence group was included in the negative group. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of MRI parameter values for the prognosis of patients with hepatocellular carcinoma.Results The high expression of antigen identified by monoclonal antibody (Ki-67) and the positive expression of cytokeratin 19 (CK19) in hepatocellular carcinoma group were higher than those in benign liver disease group (P < 0.05). T1, perfusion fraction (f) and pseudo diffusion coefficient (D*) in hepatocellular carcinoma group were higher than those in benign liver disease group, while T2, true diffusion coefficient (D) and apparent diffusion coefficient (ADC) were lower than those in benign liver disease group (P < 0.05). The T1, f and D* of patients with clinical stage Ⅲ to Ⅳ, tumor diameter ≥ 5 cm, liver function Child-Pugh grade B/C, tissue Ki-67 high expression and tissue CK19 positive expression were higher than those of patients with clinical stage Ⅰ to Ⅱ, tumor diameter < 5 cm, liver function Child-Pugh grade A, tissue Ki-67 low expression and tissue CK19 negative expression, and T2, D and ADC were lower (P < 0.05). T1, f and D* in the early recurrence group were higher than those in the non-early recurrence group, while D and ADC were lower (P < 0.05). The area under curve (AUC) of combined detection of T1, f, D, D* and ADC in predicting the prognosis of patients with hepatocellular carcinoma was higher than that of each single detection (P < 0.05).Conclusions The parameter values of MRI in patients with hepatocellular carcinoma were related to their pathological features, and the parameter values of MRI had higher clinical value in predicting the prognosis of patients with hepatocellular carcinoma.
[Keywords] hepatocellular carcinoma；magnetic resonance imaging；Ki-67 antigen；cell keratin 19；prognosis

CHEN Binbin   ZHAO Wensi*  

Department of Medical Imaging, Changde Hospital, XiangYa School of Medicine, Central South University (The First People's Hospital of Changde City), Changde 415000, China

Corresponding author: ZHAO W S, E-mail: 306009778@qq.com

Conflicts of interest   None.

Received  2025-12-24
Accepted  2026-04-10
DOI: 10.12015/issn.1674-8034.2026.06.010
Cite this article as CHEN B B, ZHAO W S. Predictive value of MRI parameter values for prognosis of patients with hepatocellular carcinoma[J]. Chin J Magn Reson Imaging, 2026, 17(6): 79-85. DOI:10.12015/issn.1674-8034.2026.06.010.

[1]
PAPADAKOS S P, ARGYROU A, MICHAILIDOU E, et al. C-reactive protein and management of hepatocellular carcinoma: bridging systemic inflammation and clinical prognosis[J/OL]. Liver Int, 2025, 45(9): e70278 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40762319/. DOI: 10.1111/liv.70278.
[2]
SU W R, LU Z Y, XUAN Z H, et al. Potential mechanism of Ganoderma Lucidum Propolis Capsules against hepatocellular carcinoma based on network pharmacology and single cell transcriptome analysis[J]. Northwest Pharm J, 2024, 39(6): 27-37. DOI: 10.3969/j.issn.1004-2407.2024.06.004.
[3]
ENNIN E, MALLEPALLY N, ALI M, et al. High grade hepatotoxicity from dual checkpoint inhibitors is more common in hepatocellular carcinoma than other cancers[J/OL]. Liver Int, 2025, 45(9): e70255 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40778804/. DOI: 10.1111/liv.70255.
[4]
HE S L, ZHANG Y L, XU J J, et al. Systematic analysis identifies CDKN2A as a prognostic biomarker for hepatocellular carcinoma[J/OL]. Discov Oncol, 2025, 16(1): 1657 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40884619/. DOI: 10.1007/s12672-025-03496-x.
[5]
LI Y, CHEN Z L, WANG D D, et al. Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma[J/OL]. Sig Transduct Target Ther, 2025, 10: 274 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40866361/. DOI: 10.1038/s41392-025-02367-9.
[6]
JIA L L, LI Z Y, HUANG G, et al. Macrotrabecular-massive subtype in hepatocellular carcinoma based on contrast-enhanced CT: deep learning outperforms machine learning[J/OL]. Insights Imaging, 2025, 16(1): 186 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40875079/. DOI: 10.1186/s13244-025-02063-w.
[7]
JIANG H L, WANG X H, ZHU Z H, et al. DCAF7 recruits USP2 to facilitate hepatocellular carcinoma progression by suppressing clockophagy-induced ferroptosis[J/OL]. Cell Death Dis, 2025, 16(1): 654 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40877242/. DOI: 10.1038/s41419-025-07977-3.
[8]
LIU H, YAN H Y, HUANG Y, et al. Metabolic genes interaction perturbation network identified and validated CD24 as a novel prognostic gene in hepatocellular carcinoma[J/OL]. Discov Oncol, 2025, 16(1): 1643 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40864324/. DOI: 10.1007/s12672-025-03232-5.
[9]
ZHANG P R, ZHUO J Y, LI H G, et al. A serum TNFR2-based model effectively predicates preoperative microvascular invasion and stratifies the tumor recurrence risk in hepatocellular carcinoma[J/OL]. BMC Gastroenterol, 2025, 25(1): 622 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40866831/. DOI: 10.1186/s12876-025-04152-y.
[10]
ZHANG N, YANG Y, LIN K, et al. Contrast-enhanced ultrasound for diagnosing subtypes of intrahepatic cholangiocarcinoma: a comparative study with poorly differentiated hepatocellular carcinoma[J/OL]. Cancer Imaging, 2025, 25(1): 107 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40866908/. DOI: 10.1186/s40644-025-00923-8.
[11]
DU J J, YANG F, DONG W, et al. Revisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma[J/OL]. World J Surg Oncol, 2025, 23(1): 323 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40866921/. DOI: 10.1186/s12957-025-03963-3.
[12]
ODAT R M, HUSSAIN H A H, ALSHWAYYAT S, et al. Global air pollution exposure and hepatocellular carcinoma: a systematic review and meta-analysis of epidemiological studies[J/OL]. BMC Public Health, 2025, 25(1): 2972 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40885956/. DOI: 10.1186/s12889-025-24162-5.
[13]
RACHI T, TOCHINAI T. Early prediction of proton therapy dose distributions and DVHs for hepatocellular carcinoma using contour-based CNN models from diagnostic CT and MRI[J/OL]. Radiat Oncol, 2025, 20(1): 122 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40759962/. DOI: 10.1186/s13014-025-02708-6.
[14]
Medical Administration and Hospital Authority of Health and Family Planning Commission of the People's Republic of China. Diagnostic and therapeutic criteria for primary liver cancer (2019 edition)[J]. Chin J of Hepatology, 2020, 19(1): 1-20. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.001.
[15]
SUN Z C, CHANG Z B, LI Z C, et al. Impact of Chinese Liver Cancer Staging on perioperative safety and prognosis in patients undergoing hepatectomy for hepatocellular carcinoma resection[J]. Chin J Cancer Prev Treat, 2025, 32(8): 509-516. DOI: 10.16073/j.cnki.cjcpt.2025.08.08.
[16]
ZHANG T Y, ZHOU B Q, GU C Y. The evaluation value of serum VEGF, CTGF and TGF-1 levels in child-pugh grade of liver function and disease prognosis in patients with CHB cirrhosis[J]. Chin J Integr Tradit West Med Liver Dis, 2022, 32(5): 440-442, 446. DOI: 10.3969/j.issn.1005-0264.2022.05.013.
[17]
CHEN C Y, ZHANG W Q, XIE Y, et al. Association of the expression of Ki67 with the prognosis of liver transplantation in patients with hepatocellular carcinoma[J]. Tianjin Med J, 2022, 50(11): 1177-1181. DOI: 10.11958/20220912.
[18]
MATUSCHEWSKI N J, SOBIREY R, REVZIN M, et al. Noninvasive tumor profiling: quantitative contrast-enhanced MRI markers predict PD-L1 and CTNNB1 status in hepatocellular carcinoma[J/OL]. Radiology, 2025, 316(2): e242750 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40762840/. DOI: 10.1148/radiol.242750.
[19]
KONOŠENOKA K M, ZDANOVSKIS N, KRATOVSKA A, et al. Comparison of apparent diffusion coefficient values on diffusion-weighted MRI for differentiating hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J/OL]. Diagnostics (Basel), 2025, 15(15): 1861 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40804826/. DOI: 10.3390/diagnostics15151861.
[20]
MAUNG S T, TANPOWPONG N, SATJA M, et al. Non-contrast abbreviated MRI for the detection of hepatocellular carcinoma in patients with Liver Imaging Reporting and Data System LR-3 and LR-4 observations in MRI[J]. Br J Radiol, 2024, 97(1162): 1671-1682. DOI: 10.1093/bjr/tqae140.
[21]
HWANG S H, RHEE H. Pushing the limit of hepatocellular carcinoma diagnosis: diagnosis of subcentimetre HCC using gadoxetic acid–enhanced MRI and alpha-fetoprotein[J]. Eur Radiol, 2024, 34(4): 2269-2270. DOI: 10.1007/s00330-023-10376-x.
[22]
LI B R, YU Y Y, XIA T Y. Editorial for "intertumoral heterogeneity based on MRI radiomic features estimates recurrence in hepatocellular carcinoma"[J]. Magnetic Resonance Imaging, 2025, 61(1): 182-183. DOI: 10.1002/jmri.29433.
[23]
KIM T H, WOO S, LEE D H, et al. MRI imaging features for predicting macrotrabecular-massive subtype hepatocellular carcinoma: a systematic review and meta-analysis[J]. Eur Radiol, 2024, 34(10): 6896-6907. DOI: 10.1007/s00330-024-10671-1.
[24]
KIM H. The feasibility of abbreviated MRI for active surveillance of hepatocellular carcinoma[J/OL]. Radiology, 2023, 307(2): e223113 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/36692405/. DOI: 10.1148/radiol.223113.
[25]
CANNELLA R. MRI quantitative features: A bridge to hepatocellular carcinoma tumor profiling[J/OL]. Radiology, 2025, 316(2): e252216 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40762849/. DOI: 10.1148/radiol.252216.
[26]
ZHANG T, REN J L, WU H, et al. Multiparametric MRI radiomics predicts overall survival in hepatocellular carcinoma[J]. Acta Radiol, 2025, 66(8): 805-815. DOI: 10.1177/02841851251324572.
[27]
GU M T, ZOU W J, CHEN H L, et al. Multilayer perceptron deep learning radiomics model based on Gd-BOPTA MRI to identify vessels encapsulating tumor clusters in hepatocellular carcinoma: a multi-center study[J/OL]. Cancer Imaging, 2025, 25(1): 87 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/40624579/. DOI: 10.1186/s40644-025-00895-9.
[28]
HEMIDA A S, TAIE D M, EL-WAHED M M A, et al. EpCAM, Ki67, and ESM1 predict hepatocellular carcinoma recurrence after liver transplantation[J]. Appl Immunohistochem Mol Morphol, 2023, 31(9): 596-606. DOI: 10.1097/pai.0000000000001150.
[29]
JAGTAP S V. Evaluation and prediction of Ki-67 expression in hepatocellular carcinoma[J/OL]. World J Gastrointest Oncol, 2025, 17(10): 106529 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/41114092/. DOI: 10.4251/wjgo.v17.i10.106529.
[30]
RAMOS-SANTILLAN V, OSHI M, NELSON E, et al. High Ki67 gene expression is associated with aggressive phenotype in hepatocellular carcinoma[J]. World J Oncol, 2024, 15(2): 257-267. DOI: 10.14740/wjon1751.
[31]
ZHUO J Y, LI H G, ZHANG P R, et al. The advances in the diagnosis and treatment of CK19-positive hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2025, 24(5): 473-475. DOI: 10.1016/j.hbpd.2025.08.003.
[32]
LIANG L, PANG J S, GAO R Z, et al. Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma[J]. Abdom Radiol (NY), 2025, 50(8): 3516-3529. DOI: 10.1007/s00261-025-04799-x.
[33]
YANG C L, XIANG W Y, WU Z Z, et al. CK19 protein expression: the best cutoff value on the prognosis and the prognosis model of hepatocellular carcinoma[J/OL]. BMC Cancer, 2025, 25(1): 55 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/39789507/. DOI: 10.1186/s12885-024-13399-9.
[34]
HAN S, MENG F, ZHANG H K, et al. Correlation analysis of Ki67, Ck19 with clinicopathological features and apparent diffusion coefficient value of hepatocellular carcinoma[J]. Natl Med J China, 2021, 101(11): 798-802. DOI: 10.3760/cma.j.cn112137-20210108-00058.
[35]
QIN Q, DENG L P, CHEN J, et al. The value of MRI in predicting hepatocellular carcinoma with cytokeratin 19 expression: a systematic review and meta-analysis[J/OL]. Clin Radiol, 2023, 78(12): e975-e984 [2025-12-23]. https://pubmed.ncbi.nlm.nih.gov/37783612/. DOI: 10.1016/j.crad.2023.08.013.
[36]
GUO X H, TIAN C Q, LIU G L, et al. Diagnostic efficacy of contrast-enhanced ultrasound, dynamic contrast-enhanced MRI combined with tumor markers AFP and DCP for primary hepatocellular carcinoma[J]. Biotechnol Genet Eng Rev, 2024, 40(1): 623-637. DOI: 10.1080/02648725.2023.2186359.

PREV Value of cardiac magnetic resonance in patients with late-onset cardiac phenotype fabry disease carrying the c.640-801G &gt; A mutation
NEXT Nomogram model based on MRI and clinical features to early predict the surgical timing of laparoscopic cholecystectomy in non-severe acute biliary pancreatitis
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn